Fanconi anaemia and cancer: an intricate relationship (original) (raw)

• Lobitz, S. & Velleuer, E. Guido Fanconi (1892–1979): a jack of all trades. Nat. Rev. Cancer 6, 893–898 (2006).
  Article CAS PubMed Google Scholar
• Ameziane, N. et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat. Commun. 6, 8829 (2015).
  Article PubMed CAS Google Scholar
• Wang, A. T. et al. A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination. Mol. Cell 59, 478–490 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Tischkowitz, M. D. et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18, 420–425 (2004).
  Article CAS PubMed Google Scholar
• Tischkowitz, M. et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br. J. Haematol. 123, 469–471 (2003).
  Article CAS PubMed Google Scholar
• Hess, C. J. et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol. 30, 299–306 (2008).
  PubMed PubMed Central CAS Google Scholar
• Alter, B. P. & Rosenberg, P. S. VACTERL-H association and Fanconi anemia. Mol. Syndromol 4, 87–93 (2013).
  CAS PubMed Google Scholar
• Neveling, K., Endt, D., Hoehn, H. & Schindler, D. Genotype-phenotype correlations in Fanconi anemia. Mutat. Res. 668, 73–91 (2009).
  Article CAS PubMed Google Scholar
• Auerbach, A. D. Fanconi anemia and its diagnosis. Mutat. Res. 668, 4–10 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Shimamura, A. & Alter, B. P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 24, 101–122 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Zhu, A. X., D'Andrea, A. D., Sahani, D. V. & Hasserjian, R. P. Case records of the Massachusetts General Hospital. Case 13–2006. A 50-year-old man with a painful bone mass and lesions in the liver. N. Engl. J. Med. 354, 1828–1837 (2006).
  Article CAS PubMed Google Scholar
• Huck, K. et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age — a paradigm. Br. J. Haematol. 133, 188–197 (2006).
  Article CAS PubMed Google Scholar
• Rochowski, A. et al. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leuk. Res. 36, 29–31 (2012).
  Article PubMed Google Scholar
• Sharma, R. & Nalepa, G. Evaluation and management of chronic pancytopenia. Pediatr. Rev. 37, 101–111 (2016).
  Article PubMed PubMed Central Google Scholar
• Tamary, H. et al. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry. Haematologica 95, 1300–1307 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Rosenberg, P. S., Tamary, H. & Alter, B. P. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi anemia in the United States and Israel. Am. J. Med. Genet. A 155A, 1877–1883 (2011).
  Article PubMed Google Scholar
• Callen, E. et al. A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood 105, 1946–1949 (2005).
  Article CAS PubMed Google Scholar
• Rosendorff, J., Bernstein, R., Macdougall, L. & Jenkins, T. Fanconi anemia: another disease of unusually high prevalence in the Afrikaans population of South Africa. Am. J. Med. Genet. 27, 793–797 (1987).
  Article CAS PubMed Google Scholar
• Yagasaki, H. et al. Two common founder mutations of the fanconi anemia group G gene FANCG/XRCC9 in the Japanese population. Hum. Mutat. 21, 555 (2003).
  Article CAS PubMed Google Scholar
• Morgan, N. V. et al. A common Fanconi anemia mutation in black populations of sub-Saharan Africa. Blood 105, 3542–3544 (2005).
  Article CAS PubMed Google Scholar
• Tipping, A. J. et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc. Natl Acad. Sci. USA 98, 5734–5739 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649–4654 (2002).
  Article CAS PubMed Google Scholar
• Hays, L. et al. Fanconi Anemia: Guidelines for Diagnosis and Management 4 edn (Fanconi Anemia Research Fund, 2014).
  Google Scholar
• Kutler, D. I. et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249–1256 (2003). This large long-term observational cohort study reports a high risk of cancer (23%) and BMF (80%) in 754 patients with FA over 20 years.
  Article CAS PubMed Google Scholar
• Paustian, L. et al. Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. Pediatr. Hematol. Oncol. 33, 5–12 (2016).
  Article CAS PubMed Google Scholar
• Velazquez, I. & Alter, B. P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am. J. Hematol. 77, 257–267 (2004).
  Article CAS PubMed Google Scholar
• Schifferli, A. & Kuhne, T. Fanconi anemia: overview of the disease and the role of hematopoietic transplantation. J. Pediatr. Hematol. Oncol. 37, 335–343 (2015).
  Article CAS PubMed Google Scholar
• Torjemane, L. et al. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Pediatr. Blood Cancer 46, 496–500 (2006).
  Article CAS PubMed Google Scholar
• Alter, B. P. Fanconi anemia and the development of leukemia. Best Pract. Res. Clin. Haematol. 27, 214–221 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Alter, B. P. et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol. 150, 179–188 (2010). This study provides quantitative data regarding the risk and spectrum of malignancies in patients with FA and other inherited BMF syndromes enrolled in the National Cancer Institute Inherited BMF Syndromes (IBMFS) registry.
  PubMed PubMed Central Google Scholar
• Kutler, D. I. et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129, 106–112 (2003).
  Article PubMed Google Scholar
• Rosenberg, P. S., Socie, G., Alter, B. P. & Gluckman, E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 105, 67–73 (2005).
  Article CAS PubMed Google Scholar
• Ellis, N. A. et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83, 655–666 (1995).
  Article CAS PubMed Google Scholar
• Ellis, N. A., Proytcheva, M., Sanz, M. M., Ye, T. Z. & German, J. Transfection of BLM into cultured bloom syndrome cells reduces the sister-chromatid exchange rate toward normal. Am. J. Hum. Genet. 65, 1368–1374 (1999).
  Article PubMed PubMed Central CAS Google Scholar
• Cunniff, C., Bassetti, J. A. & Ellis, N. A. Bloom's syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol. Syndromol 8, 4–23 (2017).
  Article CAS PubMed Google Scholar
• Wechsler, T., Newman, S. & West, S. C. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 471, 642–646 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Naim, V. & Rosselli, F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nature Cell Biol. 11, 761–768 (2009). This study reports that FANCD2 localizes to mitotic anaphase bridges resulting from interphase replication stress and recruits the BLM helicase to prevent chromosome damage and genomic instability.
  Article CAS PubMed Google Scholar
• Schurman, S. H. et al. Direct and indirect roles of RECQL4 in modulating base excision repair capacity. Hum. Mol. Genet. 18, 3470–3483 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Croteau, D. L., Singh, D. K., Hoh Ferrarelli, L., Lu, H. & Bohr, V. A. RECQL4 in genomic instability and aging. Trends Genet. 28, 624–631 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Kitao, S. et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat. Genet. 22, 82–84 (1999).
  Article CAS PubMed Google Scholar
• Van Maldergem, L. et al. Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene. J. Med. Genet. 43, 148–152 (2006).
  Article CAS PubMed Google Scholar
• Siitonen, H. A. et al. The mutation spectrum in RECQL4 diseases. Eur. J. Hum. Genet. 17, 151–158 (2009).
  Article CAS PubMed Google Scholar
• Wang, L. L. et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J. Natl Cancer Inst. 95, 669–674 (2003).
  Article CAS PubMed Google Scholar
• Carlson, A. M., Lindor, N. M. & Litzow, M. R. Therapy-related myelodysplasia in a patient with Rothmund-Thomson syndrome. Eur. J. Haematol. 86, 536–540 (2011).
  Article PubMed Google Scholar
• Kraemer, K. H. & DiGiovanna, J. J. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health. Photochem. Photobiol. 91, 452–459 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Bradford, P. T. et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J. Med. Genet. 48, 168–176 (2011).
  Article PubMed Google Scholar
• Bogliolo, M. et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am. J. Hum. Genet. 92, 800–806 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Kashiyama, K. et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am. J. Hum. Genet. 92, 807–819 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).
  Article CAS PubMed Google Scholar
• Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).
  PubMed PubMed Central CAS Google Scholar
• Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25, 1329–1333 (2007).
  Article PubMed Google Scholar
• Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606–609 (2002). This work demonstrates that inactivation of both BRCA2 alleles causes FA, providing direct clinical evidence of the genetic relationship between FA and hereditary breast and ovarian cancer predisposition syndromes.
  Article CAS PubMed Google Scholar
• Alter, B. P., Rosenberg, P. S. & Brody, L. C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J. Med. Genet. 44, 1–9 (2007).
  Article CAS PubMed Google Scholar
• Myers, K. et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr. Blood Cancer 58, 462–465 (2012).
  Article PubMed Google Scholar
• Sawyer, S. L. et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 5, 135–142 (2015).
  Article CAS PubMed Google Scholar
• Domchek, S. M. et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 3, 399–405 (2013).
  Article CAS PubMed Google Scholar
• Xia, B. et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719–729 (2006).
  Article CAS PubMed Google Scholar
• Levitus, M. et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 37, 934–935 (2005).
  Article CAS PubMed Google Scholar
• Levran, O. et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet. 37, 931–933 (2005).
  Article CAS PubMed Google Scholar
• Easton, D. F. et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J. Med. Genet. 53, 298–309 (2016).
  Article PubMed CAS Google Scholar
• Berwick, M. et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 67, 9591–9596 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Laitman, Y. et al. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. Cancer Genet. 209, 70–74 (2016).
  Article CAS PubMed Google Scholar
• Thompson, E. R. et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 8, e1002894 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Couch, F. J. et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 65, 383–386 (2005).
  CAS PubMed Google Scholar
• Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336–2346 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Virts, E. L. et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum. Mol. Genet. 24, 5093–5108 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kiiski, J. I. et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 111, 15172–15177 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Katzke, V. A., Kaaks, R. & Kuhn, T. Lifestyle and cancer risk. Cancer J. 21, 104–110 (2015).
  Article PubMed Google Scholar
• Umar, A., Dunn, B. K. & Greenwald, P. Future directions in cancer prevention. Nat. Rev. Cancer 12, 835–848 (2012).
  Article CAS PubMed Google Scholar
• Feinberg, A. P., Koldobskiy, M. A. & Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Shen, Y. et al. Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. Oncotarget 6, 20396–20403 (2015).
  PubMed PubMed Central Google Scholar
• Xie, Y. et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br. J. Haematol. 111, 1057–1064 (2000).
  Article CAS PubMed Google Scholar
• van der Heijden, M. S., Yeo, C. J., Hruban, R. H. & Kern, S. E. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 63, 2585–2588 (2003).
  CAS PubMed Google Scholar
• Wreesmann, V. B., Estilo, C., Eisele, D. W., Singh, B. & Wang, S. J. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec. 69, 218–225 (2007).
  Article CAS PubMed Google Scholar
• Kais, Z. et al. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep. 15, 2488–2499 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Michl, J., Zimmer, J., Buffa, F. M., McDermott, U. & Tarsounas, M. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat. Struct. Mol. Biol. 23, 755–757 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Kauffmann, A. et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27, 565–573 (2008).
  Article CAS PubMed Google Scholar
• Ozawa, H. et al. FANCD2 mRNA overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer. Ann. Surg. Oncol. 17, 2341–2348 (2010).
  Article PubMed Google Scholar
• Strub, T. et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 30, 2319–2332 (2011).
  Article CAS PubMed Google Scholar
• Bourseguin, J. et al. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Sci. Rep. 6, 36539 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189–203 (2012).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  CAS PubMed Google Scholar
• Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016–1036 (2017).
  PubMed PubMed Central CAS Google Scholar
• Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Castro-Giner, F., Ratcliffe, P. & Tomlinson, I. The mini-driver model of polygenic cancer evolution. Nat. Rev. Cancer 15, 680–685 (2015).
  Article CAS PubMed Google Scholar
• Krem, M. M., Press, O. W., Horwitz, M. S. & Tidwell, T. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. Br. J. Haematol. 171, 13–28 (2015).
  Article CAS PubMed Google Scholar
• Barber, L. J., Davies, M. N. & Gerlinger, M. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr. Opin. Genet. Dev. 30, 1–6 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Shlush, L. I. & Hershkovitz, D. Clonal evolution models of tumor heterogeneity. Am. Soc. Clin. Oncol. Educ. Book, e662–5 (2015).
• Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93–115 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009).
  Article CAS PubMed Google Scholar
• Salazar-Roa, M. & Malumbres, M. Fueling the cell division cycle. Trends Cell Biol. 27, 69–81 (2017).
  Article CAS PubMed Google Scholar
• Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78–81 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43–47 (2016).
  Article CAS PubMed Google Scholar
• Park, E. et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol. Cell 50, 908–918 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Awasthi, P., Foiani, M. & Kumar, A. ATM and ATR signaling at a glance. J. Cell Sci. 128, 4255–4262 (2015).
  Article CAS PubMed Google Scholar
• Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801–817 (2017).
  Article CAS PubMed Google Scholar
• Warfel, N. A. & El-Deiry, W. S. p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 25, 52–58 (2013).
  Article CAS PubMed Google Scholar
• Collins, N. B. et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 113, 2181–2190 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, X. et al. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol. Cell. Biol. 27, 3098–3108 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Singh, T. R. et al. ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions. Cancer Res. 73, 4300–4310 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Xie, J. et al. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J. Clin. Invest. 125, 1523–1532 (2015).
  Article PubMed PubMed Central Google Scholar
• Yamamoto, K. N. et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc. Natl Acad. Sci. USA 108, 6492–6496 (2011).
  Article PubMed PubMed Central Google Scholar
• Lachaud, C. et al. Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia. J. Cell Sci. 127, 2811–2817 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Gwon, G. H. et al. Crystal structure of a Fanconi anemia-associated nuclease homolog bound to 5′ flap DNA: basis of interstrand cross-link repair by FAN1. Genes Dev. 28, 2276–2290 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Sobeck, A. et al. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol. Cell. Biol. 26, 425–437 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966–977 (2011).
  CAS PubMed Google Scholar
• Segurado, M. & Diffley, J. F. Separate roles for the DNA damage checkpoint protein kinases in stabilizing DNA replication forks. Genes Dev. 22, 1816–1827 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Pichierri, P. & Rosselli, F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 23, 1178–1187 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Schwab, R. A. et al. The Fanconi anemia pathway maintains genome stability by coordinating replication and transcription. Mol. Cell 60, 351–361 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106–116 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467–480 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Kim, Y. et al. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 43, 142–146 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Stoepker, C. et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 43, 138–141 (2011).
  Article CAS PubMed Google Scholar
• Wang, R. et al. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1. Science 346, 1127–1130 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Smogorzewska, A. et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol. Cell 39, 36–47 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Long, D. T., Raschle, M., Joukov, V. & Walter, J. C. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science 333, 84–87 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Vaz, F. et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat. Genet. 42, 406–409 (2010).
  Article CAS PubMed Google Scholar
• Schwab, R. A., Blackford, A. N. & Niedzwiedz, W. ATR activation and replication fork restart are defective in FANCM-deficient cells. EMBO J. 29, 806–818 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell 39, 25–35 (2010).
  Article CAS PubMed Google Scholar
• Pace, P. et al. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 329, 219–223 (2010). References 119 and 120 suggest that excessive use of alternative repair strategies based on non-HR owing to defective HR-based repair is detrimental to cells deficient in the FA pathway.
  Article CAS PubMed Google Scholar
• Renaud, E., Barascu, A. & Rosselli, F. Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells. Nucleic Acids Res. 44, 648–656 (2016).
  Article CAS PubMed Google Scholar
• Blunt, T. et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc. Natl Acad. Sci. USA 93, 10285–10290 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Houghtaling, S. et al. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum. Mol. Genet. 14, 3027–3033 (2005).
  Article CAS PubMed Google Scholar
• Bunting, S. F. et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol. Cell 46, 125–135 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Ceccaldi, R., Sarangi, P. & D'Andrea, A. D. The Fanconi anaemia pathway: new players and new functions. Nat. Rev. Mol. Cell Biol. 17, 337–349 (2016).
  Article CAS PubMed Google Scholar
• Lossaint, G. et al. FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. Mol. Cell 51, 678–690 (2013).
  Article CAS PubMed Google Scholar
• Nalepa, G. et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J. Clin. Invest. 123, 3839–3847 (2013). This study shows an impaired SAC and accumulation of supernumerary centrosomes in primary cells of patients with FA owing to mutations in 1 of 12 different FA genes, implicating the FA pathway in genome maintenance through control of the centrosome cycle and cell division beyond the interphase DDR.
  Article PubMed PubMed Central CAS Google Scholar
• Nam, H. J., Naylor, R. M. & van Deursen, J. M. Centrosome dynamics as a source of chromosomal instability. Trends Cell Biol. 25, 65–73 (2015).
  Article CAS PubMed Google Scholar
• Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278–282 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• de Carcer, G. & Malumbres, M. A centrosomal route for cancer genome instability. Nature Cell Biol. 16, 504–506 (2014).
  Article CAS PubMed Google Scholar
• Abdul-Sater, Z. et al. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. Exp. Hematol. 43, 1031–1046.e12 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Vinciguerra, P., Godinho, S. A., Parmar, K., Pellman, D. & D'Andrea, A. D. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J. Clin. Invest. 120, 3834–3842 (2010). This work demonstrates that at least some FA proteins function beyond the recognized interphase DDR in cytokinesis.
  Article PubMed PubMed Central CAS Google Scholar
• Zou, J. et al. FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Biol. Open 2, 1022–1031 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Kim, S. et al. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity. Int. J. Biochem. Cell Biol. 45, 1953–1961 (2013).
  Article CAS PubMed Google Scholar
• Wang, H. F., Takenaka, K., Nakanishi, A. & Miki, Y. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. Cancer Res. 71, 68–77 (2011).
  Article CAS PubMed Google Scholar
• Magron, A., Elowe, S. & Carreau, M. The Fanconi anemia C protein binds to and regulates Stathmin-1 phosphorylation. PLoS ONE 10, e0140612 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kupfer, G. M. et al. The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. Blood 90, 1047–1054 (1997). This paper describes the physical interaction between FANCC and the key mitotic CDK, CDK1.
  CAS PubMed Google Scholar
• Beretta, L., Dobransky, T. & Sobel, A. Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J. Biol. Chem. 268, 20076–20084 (1993).
  CAS PubMed Google Scholar
• Godek, K. M., Kabeche, L. & Compton, D. A. Regulation of kinetochore-microtubule attachments through homeostatic control during mitosis. Nat. Rev. Mol. Cell Biol. 16, 57–64 (2015).
  Article CAS PubMed Google Scholar
• London, N. & Biggins, S. Signalling dynamics in the spindle checkpoint response. Nat. Rev. Mol. Cell Biol. 15, 736–747 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Choi, E. et al. BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev. Cell 22, 295–308 (2012). This work suggests that the mechanism of action of one of the FA proteins, BRCA2, is in the activation of the SAC.
  Article CAS PubMed Google Scholar
• Park, I. et al. Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation. J. Cell Biol. 202, 295–309 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Chan, K. L., Palmai-Pallag, T., Ying, S. & Hickson, I. D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nature Cell Biol. 11, 753–760 (2009). This work identifies that the FANCD2–FANCI heterodimer colocalizes with the BLM helicase on mitotic chromosome bridges induced by replication stress, implicating the FA and BLM protein pathways in the prevention of micronucleation and genomic instability throughout the cell cycle.
  Article CAS PubMed Google Scholar
• Guervilly, J. H. et al. The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. Mol. Cell 57, 123–137 (2015).
  Article CAS PubMed Google Scholar
• Ouyang, J. et al. Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. Mol. Cell 57, 108–122 (2015).
  Article CAS PubMed Google Scholar
• Ouyang, K. J. et al. SUMO modification regulates BLM and RAD51 interaction at damaged replication forks. PLoS Biol. 7, e1000252 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53–58 (2012). This work elegantly describes how micronucleation resulting from chromosome mis-segregation during cell division fuels excessive mutagenesis in subsequent interphase.
  Article PubMed PubMed Central CAS Google Scholar
• Daniels, M. J., Wang, Y., Lee, M. & Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876–879 (2004). This paper shows that BRCA2 controls the cell cycle beyond the interphase DDR.
  Article CAS PubMed Google Scholar
• Jonsdottir, A. B. et al. Tetraploidy in BRCA2 breast tumours. Eur. J. Cancer 48, 305–310 (2012).
  Article CAS PubMed Google Scholar
• Jonsdottir, A. B. et al. BRCA2 heterozygosity delays cytokinesis in primary human fibroblasts. Cell Oncol. 31, 191–201 (2009).
  PubMed PubMed Central CAS Google Scholar
• Takaoka, M., Saito, H., Takenaka, K., Miki, Y. & Nakanishi, A. BRCA2 phosphorylated by PLK1 moves to the midbody to regulate cytokinesis mediated by nonmuscle myosin IIC. Cancer Res. 74, 1518–1528 (2014).
  Article CAS PubMed Google Scholar
• Mondal, G. et al. BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev. Cell 23, 137–152 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Pawlikowska, P., Fouchet, P., Vainchenker, W., Rosselli, F. & Naim, V. Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca −/− mice. Blood 124, 3613–3623 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Alavattam, K. G. et al. Elucidation of the Fanconi anemia protein network in meiosis and its function in the regulation of histone modifications. Cell Rep. 17, 1141–1157 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Kato, Y. et al. FANCB is essential in the male germline and regulates H3K9 methylation on the sex chromosomes during meiosis. Hum. Mol. Genet. 24, 5234–5249 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Cuomo, M. E. et al. p53-driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nature Cell Biol. 10, 723–730 (2008).
  Article CAS PubMed Google Scholar
• Mikule, K. et al. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nature Cell Biol. 9, 160–170 (2007).
  Article CAS PubMed Google Scholar
• Ceccaldi, R. et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 11, 36–49 (2012). This study demonstrates that inhibition of p53-induced cell cycle arrest promotes proliferation of cells with deficiencies in the FA pathway ex vivo and in vivo , implicating the p53 DDR in FA-associated BMF.
  Article PubMed PubMed Central CAS Google Scholar
• Ceccaldi, R. et al. Spontaneous abrogation of the G2DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J. Clin. Invest. 121, 184–194 (2011).
  Article CAS PubMed Google Scholar
• Freie, B. et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102, 4146–4152 (2003). This study shows that Fancc −/− mice develop a variety of malignancies upon Trp53 -knockout, highlighting the importance of a functional p53 pathway in preventing FA-associated cancers in vivo.
  Article CAS PubMed Google Scholar
• Woo, H. I. et al. Acute myeloid leukemia with complex hypodiploidy and loss of heterozygosity of 17p in a boy with Fanconi anemia. Ann. Clin. Lab Sci. 41, 66–70 (2011).
  PubMed Google Scholar
• Quentin, S. et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117, e161–170 (2011).
  Article CAS PubMed Google Scholar
• Zanier, R., Briot, D., Dugas du Villard, J. A., Sarasin, A. & Rosselli, F. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Oncogene 23, 5004–5013 (2004).
  Article CAS PubMed Google Scholar
• Rathbun, R. K. et al. Interferon-γ-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 96, 4204–4211 (2000).
  CAS PubMed Google Scholar
• Haneline, L. S. et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac −/− mice. Blood 91, 4092–4098 (1998).
  CAS PubMed Google Scholar
• Rathbun, R. K. et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 90, 974–985 (1997).
  CAS PubMed Google Scholar
• Li, J. et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J. Clin. Invest. 117, 3283–3295 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Du, W., Erden, O. & Pang, Q. TNF-α signaling in Fanconi anemia. Blood Cells Mol. Dis. 52, 2–11 (2014).
  Article CAS PubMed Google Scholar
• Fagerlie, S. R. & Bagby, G. C. Immune defects in Fanconi anemia. Crit. Rev. Immunol. 26, 81–96 (2006).
  Article CAS PubMed Google Scholar
• Sies, H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 4, 180–183 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013).
  Article CAS PubMed Google Scholar
• Fritz, K. S. & Petersen, D. R. An overview of the chemistry and biology of reactive aldehydes. Free Radic. Biol. Med. 59, 85–91 (2013).
  Article CAS PubMed Google Scholar
• Kumari, U., Ya Jun, W., Huat Bay, B. & Lyakhovich, A. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. Oncogene 33, 165–172 (2014).
  Article CAS PubMed Google Scholar
• Baan, R. et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 8, 292–293 (2007).
  Article PubMed Google Scholar
• Phillips, D. H. & Venitt, S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. Int. J. Cancer 131, 2733–2753 (2012).
  Article CAS PubMed Google Scholar
• Chang, J. S., Hsiao, J. R. & Chen, C. H. ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective. J. Biomed. Sci. 24, 19 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Klyosov, A. A., Rashkovetsky, L. G., Tahir, M. K. & Keung, W. M. Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Biochemistry 35, 4445–4456 (1996).
  Article CAS PubMed Google Scholar
• Brooks, P. J., Enoch, M. A., Goldman, D., Li, T. K. & Yokoyama, A. The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Med. 6, e50 (2009).
  Article CAS PubMed Google Scholar
• Harada, S., Agarwal, D. P. & Goedde, H. W. Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese. Lancet 2, 982 (1981).
  Article CAS PubMed Google Scholar
• Joenje, H., Arwert, F., Eriksson, A. W., de Koning, H. & Oostra, A. B. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 290, 142–143 (1981). This is the first paper to demonstrate that chromosome breakage in cells with deficiencies in the FA pathway is exacerbated by oxygen exposure.
  Article CAS PubMed Google Scholar
• Pagano, G. et al. Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways. Eur. J. Haematol. 91, 141–151 (2013).
  Article CAS PubMed Google Scholar
• Du, W. et al. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 119, 4142–4151 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Mukhopadhyay, S. S. et al. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J. Cell Biol. 175, 225–235 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Saadatzadeh, M. R., Bijangi-Vishehsaraei, K., Hong, P., Bergmann, H. & Haneline, L. S. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway. J. Biol. Chem. 279, 16805–16812 (2004).
  Article CAS PubMed Google Scholar
• Uziel, O. et al. Oxidative stress causes telomere damage in Fanconi anaemia cells — a possible predisposition for malignant transformation. Br. J. Haematol. 142, 82–93 (2008).
  Article CAS PubMed Google Scholar
• Pagano, G. et al. In vitro hypersensitivity to oxygen of Fanconi anemia (FA) cells is linked to ex vivo evidence for oxidative stress in FA homozygotes and heterozygotes. Blood 89, 1111–1112 (1997).
  CAS PubMed Google Scholar
• Wilson, H. D., Wilson, J. R. & Fuchs, P. N. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res. 1098, 126–128 (2006).
  Article CAS PubMed Google Scholar
• Hadjur, S. et al. Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase. Blood 98, 1003–1011 (2001).
  Article CAS PubMed Google Scholar
• Langevin, F., Crossan, G. P., Rosado, I. V., Arends, M. J. & Patel, K. J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53–58 (2011).
  Article CAS PubMed Google Scholar
• Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571–575 (2012). References 189 and 190 demonstrate that deletion of Aldh2 exacerbates perinatal lethality, predisposition to leukaemia and alcohol-induced BMF, and impaired HSC fitness in Fancd2 −/− mice, implicating endogenous aldehydes and alcohol intake in in vivo manifestations of FA.
  Article CAS PubMed Google Scholar
• Oberbeck, N. et al. Maternal aldehyde elimination during pregnancy preserves the fetal genome. Mol. Cell 55, 807–817 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Pontel, L. B. et al. Endogenous formaldehyde is a hematopoietic stem cell genotoxin and metabolic carcinogen. Mol. Cell 60, 177–188 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Hira, A. et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122, 3206–3209 (2013). This work demonstrates how a candidate modifier gene may affect the clinical course of FA in a susceptible population, lending clinical support to the proposed role of aldehyde-mediated oxidative stress in the pathogenesis of FA.
  Article PubMed PubMed Central CAS Google Scholar
• Brooks, P. J. & Zakhari, S. Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis. Environ. Mol. Mutag. 55, 77–91 (2014).
  Article CAS Google Scholar
• Zhang, Q. S. et al. Fancd2 −/− mice have hematopoietic defects that can be partially corrected by resveratrol. Blood 116, 5140–5148 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Zhang, Q. S. et al. Evaluation of resveratrol and _N_-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model. Pediatr. Blood Cancer 61, 740–742 (2014).
  Article PubMed Google Scholar
• Hamidieh, A. A. et al. Calcitriol for oral mucositis prevention in patients with fanconi anemia undergoing hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Am. J. Ther. 23, e1700–e1708 (2016).
  Article PubMed Google Scholar
• Nam, J. S. et al. Application of bioactive quercetin in oncotherapy: from nutrition to nanomedicine. Molecules 21, E108 (2016).
  Article PubMed Google Scholar
• Leyva-Lopez, N., Gutierrez-Grijalva, E. P., Ambriz-Perez, D. L. & Heredia, J. B. Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. Int. J. Mol. Sci. 17, E921 (2016).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01720147 (2017).
• Taniguchi, T. et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568–574 (2003). This work demonstrates that somatic inactivation of the FA pathway occurs in a fraction of primary ovarian tumour cells and cell lines, suggesting a rationale for future targeted therapies.
  Article CAS PubMed Google Scholar
• Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
  Article CAS PubMed Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005). References 202 and 203 demonstrate that single-agent PARP inhibition selectively inhibits BRCA2-deficient and BRCA1-deficient tumour growth in mouse xenografts and kills tumour cells, confirming the clinically important synthetic lethality between loss of BRCA tumour suppressors and inhibition of PARP.
  Article CAS PubMed Google Scholar
• Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009). This is a clinical study that demonstrates the antitumour activity of a PARP inhibitor in patients with inherited BRCA1 and BRCA2 mutations.
  CAS PubMed Google Scholar
• Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440–1449 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244–250 (2015).
  Article CAS PubMed Google Scholar
• Kim, G. et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline brca-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257–4261 (2015).
  Article CAS PubMed Google Scholar
• Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555–3561 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
  Article CAS PubMed Google Scholar
• Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012). References 211 and 212 present an initial phase II study demonstrating improved progression-free survival in patients with progressive ovarian cancers treated with PARP inhibitors. This effect was not limited to patients with inherited BRCA1 or BRCA2 mutations, suggesting that tumours with acquired loss of BRCA genes will respond to PARP inhibition as well.
  Article CAS PubMed Google Scholar
• Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01989546 (2017).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02571725 (2017).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02873975 (2017).
• Patil, A. A. et al. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents. Oncotarget 5, 6414–6424 (2014).
  Article PubMed PubMed Central Google Scholar
• Chirnomas, D. et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5, 952–961 (2006).
  Article CAS PubMed Google Scholar
• Landais, I. et al. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol. Cancer 8, 133 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Malric, A. et al. Fanconi anemia and solid malignancies in childhood: a national retrospective study. Pediatr. Blood Cancer 62, 463–470 (2015).
  Article PubMed Google Scholar
• Dodgshun, A. J., Sexton-Oates, A., Saffery, R. & Sullivan, M. J. Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. Cancer Genet. 209, 53–56 (2016).
  Article CAS PubMed Google Scholar
• Hirsch, B. et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103, 2554–2559 (2004).
  Article CAS PubMed Google Scholar
• Wagner, J. E. et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103, 3226–3229 (2004).
  Article CAS PubMed Google Scholar
• Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39, 162–164 (2007).
  Article CAS PubMed Google Scholar
• Faivre, L. et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. Eur. Fanconi Anemia Res. Group. Blood 96, 4064–4070 (2000).
  CAS Google Scholar
• Futaki, M. et al. The IVS4 + 4 A to T mutation of the fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 95, 1493–1498 (2000).
  CAS PubMed Google Scholar
• Parmar, K., D'Andrea, A. & Niedernhofer, L. J. Mouse models of Fanconi anemia. Mutat. Res. 668, 133–140 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Pulliam-Leath, A. C. et al. Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. Blood 116, 2915–2920 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Walter, D. et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature 520, 549–552 (2015).
  Article CAS PubMed Google Scholar
• Cerabona, D., Sun, Z. & Nalepa, G. Leukemia and chromosomal instability in aged Fancc −/− mice. Exp. Hematol. 44, 352–357 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Qiao, F. et al. Phosphorylation of fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. J. Biol. Chem. 279, 46035–46045 (2004).
  Article CAS PubMed Google Scholar
• Wilson, J. B. et al. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. Mutat. Res. 689, 12–20 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Ho, G. P., Margossian, S., Taniguchi, T. & D'Andrea, A. D. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol. Cell. Biol. 26, 7005–7015 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Ishiai, M. et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat. Struct. Mol. Biol. 15, 1138–1146 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Andreassen, P. R., D'Andrea, A. D. & Taniguchi, T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18, 1958–1963 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Taniguchi, T. et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459–472 (2002). References 235 and 236 demonstrate ATM-dependent phosphorylation and ATR-dependent monoubiquitylation of FANCD2, providing links between the DDR and the activation of key FA pathway proteins.
  Article CAS PubMed Google Scholar
• Zhi, G. et al. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res. 69, 8775–8783 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289–301 (2007). This work identifies FANCI as an FANCD2 monoubiquitylation partner in the DDR–FA signalling pathway.
  Article PubMed PubMed Central CAS Google Scholar
• Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001). This paper is one of the first to demonstrate the DNA damage-dependent and FA core complex- dependent monoubiquitylation of FANCD2 and the colocalization of FANCD2 and BRCA1 on nuclear damage-induced foci, suggesting a functional connection between these critical tumour-suppressor pathways, which is now well established.
  Article CAS PubMed Google Scholar
• Meetei, A. R. et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35, 165–170 (2003).
  Article CAS PubMed Google Scholar
• Cole, A. R., Lewis, L. P. & Walden, H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat. Struct. Mol. Biol. 17, 294–298 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Machida, Y. J. et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell 23, 589–596 (2006).
  Article CAS PubMed Google Scholar
• Hira, A. et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am. J. Hum. Genet. 96, 1001–1007 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Rickman, K. A. et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia. Cell Rep. 12, 35–41 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331–339 (2005).
  Article CAS PubMed Google Scholar
• Gibbs-Seymour, I. et al. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage. Mol. Cell 57, 150–164 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kim, J. M. et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 16, 314–320 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Parmar, K. et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 28, 1186–1195 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Liang, Q. et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol. 10, 298–304 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Bogliolo, M. & Surralles, J. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. Curr. Opin. Genet. Dev. 33, 32–40 (2015).
  Article CAS PubMed Google Scholar
• Bluteau, D. et al. Biallelic inactivation of REV7 is associated with Fanconi anemia. J. Clin. Invest. 126, 3580–3584 (2016).
  Article PubMed PubMed Central Google Scholar
• Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Dror, Y. et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann. NY Acad. Sci. 1242, 40–55 (2011).
  Article PubMed Google Scholar
• Stanley, S. E. & Armanios, M. The short and long telomere syndromes: paired paradigms for molecular medicine. Curr. Opin. Genet. Dev. 33, 1–9 (2015).
  Article PubMed PubMed Central CAS Google Scholar